Hypertrophic cardiomyopathy is disease characterized by thickening of the myocardium, leading to left ventricular hypertrophy. The disease commonly has a genetic underpinning, and is often associated with mutations in sarcomere genes. Symptom presentation in hypertrophic cardiomyopathy varies widely based on the site and extent of hypertrophy; patients may be asymptomatic or may experience fatigue, dyspnea, chest pain, and/or other manifestations. Although the evidence base for drug treatment in hypertrophic cardiomyopathy is somewhat limited, the ACCF and AHA provide management guidelines, with beta blockers and calcium-channel blockers generally serving as the cornerstone of treatment.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed hypertrophic cardiomyopathy patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hypertrophic cardiomyopathy patients?
  • What proportion of hypertrophic cardiomyopathy patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of hypertrophic cardiomyopathy patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients with hypertrophic cardiomyopathy?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms Claims Data Analysis Hypertrophic Cardiomyopathy US October 2019

Author(s): John Crowley

John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.